ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019)

(E-pub Ahead of Print)

Author(s): Elham Foroozanfar, Mohamad Forouzanfar, Tahereh Farkhondeh, Saeed Samarghandian, Fatemeh Forouzanfar*

Journal Name: Current Drug Discovery Technologies

Article ID: e130921189567
Become EABM
Become Reviewer
Call for Editor


A novel coronavirus termed nCoV-2019 caused an epidemic of acute respiratory syndrome in humans was first detected in Wuhan, China, in December 2019. nCoV-2019 resulted in thousands of cases of lethal disease all around the world. Unfortunately, there is no specific treatment yet so better understanding of the pathobiology of the disease can be helpful. The renin–angiotensin system and their products has several important physiological actions, On the other hand, this system involved in the pathogenesis of various diseases. In this context, this review article will briefly insights for understanding the role of angiotensin-converting enzyme 2 (ACE2) receptor as a potential attractive target for nCoV-2019- induced acute respiratory syndrome.

Keywords: COVID-19, renin-angiotensin system, ACE2, angiotensin, SARS-like coronavirus, acute respiratory syndrome

Rights & PermissionsPrintExport Cite as

Article Details

Article ID: e130921189567
Published on: 28 December, 2020
(E-pub Ahead of Print)
DOI: 10.2174/1570163817999201228215911
Price: $95

Article Metrics

PDF: 138